Kripthonite Therapeutics ApS

At Kripthonite Therapeutics, we are on a mission to fight the most elusive and deadly cancer cells: the hypoxic ones. Hypoxic cancer cells survive in low-oxygen environments, and consequently become resistant to most treatments, such as radiotherapy, chemotherapy, and immunotherapy. Our therapy targets the energy metabolism of these cells through a novel mechanism of action leading to selective cell killing in a matter of hours. This not only kills the cancer cells directly, but also makes the tumor vulnerable to other therapies.

 

Our lead candidate PH1154 is a breakthrough in cancer treatment. It has shown remarkable results in preclinical studies in mice in a hard-to-treat tumor model. Here, selective elimination of hypoxic tumor cells by PH1154 perfectly complemented the eradication of the normoxic bulk tumor by radiotherapy. This result demonstrates the importance of eliminating hypoxic cancer cells and suggests groundbreaking clinical potential of our approach. Thus, PH1154 has the potential to enhance the effectiveness of immunotherapy and radiation by removing the most resilient cancer cells from the tumor.

 

Join our quest to help cancer patients worldwide.